Organogenesis Holdings Inc (ORGO) Q3 2026 Earnings Call Highlights: Market Bottom, Cost Cuts, ...
Organogenesis Holdings Inc. (ORGO) Q3 2026 Earnings Call Transcript
Organogenesis Holdings Inc. Q3 2026 Earnings Call Summary
Organogenesis: 3 Key Takeaways for Long-Term Investors
Organogenesis (ORGO) Q3 2026 Earnings Call Transcript
Organogenesis Q3 Earnings Call Highlights
Organogenesis: Q3 Earnings Snapshot
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
Organogenesis Holdings Q3 2026 Earnings Call Transcript
Organogenesis Hldgs Q3 Adj. EPS $(0.25) Misses $(0.17) Estimate, Sales $45.457M Miss $52.100M Estimate
Organogenesis Holdings Narrows FY2026 Sales Guidance from $179.000M-$215.000M to $179.400M-$200.000M vs $196.050M Est
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
Organogenesis Holdings Announces Publication Of Results From PREPARE, Multicenter, RCT Evaluating PuraPlyAM Plus SoC Compared To SoC Alone In Hard-To-Heal Diabetic Foot Ulcers
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2
Organogenesis Q2 Earnings Call Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.